Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck

Author(s):
Samant, S.; Brekel, M.W. van den; Kies, M.S.; Wan, J.; Robbins, K.T.; Rosenthal, D.I.; Rasch, C.; Weber, R.S.
Published
2012
Publication type
Article / Letter to editor

Abstract

Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50%) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 452 months). Overall survival (OS), progression-free survival (PFS), and local progressionfree survival (LPFS) rates at 5 years were 87%, 39%, and 61%, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck. (C) 2011 Wiley Periodicals, Inc. Head Neck, 2012

adenoid cystic carcinomasalivary neoplasmschemoradiationdrug therapyradiation therapy
Date issued
2012-09-01
Language
English
Publisher
WILEY-BLACKWELL
Is part of
Head and Neck (2012), Vol. 34, no. 9, p. 1263-1268
hdl
1887/3281697
doi
10.1002/hed.21905